Abbott Laboratories
ABT
Ci-dessous : le cours en direct de Abbott Laboratories (ABT), un graphique 1 an, 8 indicateurs (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume) et le mode de comparaison. Ajoutez à votre portefeuille, mettez en favori ou définissez des alertes de prix.
Abbott Laboratories (ABT) est une entreprise du secteur Healthcare basée en United States. Active dans Medical Devices, elle emploie environ 122,000 personnes. Sur l'année écoulée, ABT a évolué entre 81.97 et 137.49 USD. Le PER (TTM) avoisine 28.2 pour une capitalisation d'environ 175.37B USD. Le rendement en dividendes actuel est de 2.50%.
- Prev close
- $98.83
- Volume (24h)
- $1.72B
- Market cap
- $175.37B
- Currency
- USD
Score
49/ 100 · Mitigé
- Valeur52
- Qualité74
- Momentum21
- Croissance24
- Risque79
- Dividende42
- Liquidité—
Composé à partir de données de marché publiques. Informatif uniquement — pas un conseil en investissement.
Projection de tendance
Là où la tendance récente pointe si elle se poursuit.
- +5 barres
- 101.1581 +0.47%
- +20 barres
- 101.8216 +1.13%
- +60 barres
- 102.0795 +1.39%
- +120 barres
- 102.0889 +1.40%
Continuation par régression linéaire — pas une prédiction, pas un conseil en investissement. ±1σ ≈ 68% · ±2σ ≈ 95%: ±0.0352 USD.
Interprétation
Les signaux composites paraissent mitigés. Force : profil de risque avec faiblesse : momentum. Le prix est près du tiers supérieur de la plage récente, la tendance est ascendante.
Observation descriptive — ce n'est pas un conseil en investissement.
Décomposition du score
Les valeurs brutes derrière chaque pilier pour voir ce que le score composite mesure.
- Valeur52/100
Valeur semble mitigé — porté par PER (28.2).
PER:28.2P/B:3.37PEG:1.5 - Qualité74/100
Qualité semble robuste — porté par Marge brute (56.77%).
Marge nette:11.65%Marge brute:56.77% - Momentum21/100
Momentum semble fragile — porté par Variation 52 sem (-19.08%).
Variation 52 sem:-19.08% - Croissance24/100
Croissance semble fragile — porté par Croissance BPA (-47.50%).
Croissance CA:13.00%Croissance BPA:-47.50% - Risque79/100
Risque semble solide — porté par Dette / capitaux (64.77).
Bêta:0.61Dette / capitaux:64.77Intérêts à découvert:1.50% - Dividende42/100
Dividende semble faible — porté par Taux de distribution (67.23%).
Rendement dividende:2.50%Taux de distribution:67.23%
Calculé à partir de données de marché publiques — informatif, pas un conseil en investissement.
Niveaux de référence
Retracements et extensions de Fibonacci sur la plage récente.
Référence uniquement — ce n'est pas un conseil en investissement.
Ces coordonnées décrivent les regroupements de prix passés, pas où acheter ou vendre. Faites vos propres recherches avant toute transaction.
- RésistanceExtension Fib +161.8%134.7489 USD+33.84% du prix actuel
- RésistanceExtension Fib +100%122.29 USD+21.46% du prix actuel
- RésistanceExtension Fib +61.8%114.5889 USD+13.81% du prix actuel
- RésistanceExtension Fib +27.2%107.6135 USD+6.89% du prix actuel
- Actuel100.68 USD
- SupportRetracement Fib 23.6%97.3722 USD-3.29% du prix actuel
- SupportRetracement Fib 38.2%94.4289 USD-6.21% du prix actuel
- SupportPoint médian Fib 50%92.05 USD-8.57% du prix actuel
- SupportRetracement Fib 61.8%89.6711 USD-10.93% du prix actuel
- SupportRetracement Fib 78.6%86.2842 USD-14.30% du prix actuel
- SupportExtension Fib −27.2%76.4865 USD-24.03% du prix actuel
- SupportExtension Fib −61.8%69.5111 USD-30.96% du prix actuel
- SupportExtension Fib −100%61.81 USD-38.61% du prix actuel
Financials
- 52w high
- $137.49
- 52w low
- $81.97
- 52w change
- -19.08%
- Day high
- $102.13
- Day low
- $99.47
- P/E (TTM)
- 28.2
- Forward P/E
- 16.6
- PEG
- 1.5
- Price / Book
- 3.37
- Beta (5Y)
- 0.61
- Enterprise value
- 202.85B
- EV / Revenue
- 4.35
- EV / EBITDA
- 17.09
- EPS (TTM)
- $3.57
- Forward EPS
- $6.07
- Dividend yield
- 2.50%
- Dividend rate
- $2.52
- Payout ratio
- 67.23%
- Revenue (TTM)
- 46.58B
- EBITDA
- 11.87B
- Total cash
- 7.3B
- Total debt
- 34.14B
- Debt / Equity
- 64.77
- Profit margin
- 11.65%
- Gross margin
- 56.77%
- Shares outstanding
- 1.74B
- Float
- 1.73B
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Analyst & Risk
- Beta (vs S&P 500)
- 0.61
- less volatile
- 52-week change
- -19.08%
- Short % of float
- 1.50%
- Short ratio (days)
- 1.67
- Debt / Equity
- 64.77
- very high leverage
- PEG ratio
- 1.5
- fair
- EV / Revenue
- 4.35
- EV / EBITDA
- 17.09
- Revenue growth
- 13.00%
- Earnings growth
- -47.50%
- EBITDA
- 11.87B
- Total cash
- 7.3B
- Total debt
- 34.14B
- Insider holdings
- 0.49%
- Institutional
- 82.43%
Recent rating changes
- 2026-07-17CitigroupBuy → Buymain
- 2026-07-17Piper SandlerOverweight → Overweightreit
- 2026-07-17JP MorganOverweight → Overweightmain
- 2026-07-17Wells FargoOverweight → Overweightmain
- 2026-07-17TD CowenBuy → Buyreit
- 2026-07-17Evercore ISI GroupOutperform → Outperformmain
- 2026-07-17RBC CapitalOutperform → Outperformreit
- 2026-07-17BTIGBuy → Buymain
Financial documents
- Corporate Changes & Voting Matters8-K2026-07-16
- Annual report of employee stock purchase11-K2026-06-18
- Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)SD2026-05-27
- Periodic Financial Reports10-Q2026-04-29
- Corporate Changes & Voting Matters8-K2026-04-27
- Offering RegistrationsS-82026-04-24
- Corporate Changes & Voting Matters8-K2026-04-17
- Corporate Changes & Voting Matters8-K2026-04-16
- Offering RegistrationsS-82026-03-23
- Proxy StatementsDEFA14A2026-03-13
- Corporate Changes & Voting Matters8-K2026-03-09
- Corporate Changes & Voting Matters8-K2026-02-26
Actualités récentes
- My 2 Favorite Dividend Kings to Buy Right NowMotley Fool13h ago
- The Justice Department Is Pulling Back on Prosecuting Corporate CrimeThe Wall Street Journal1d ago
- ABT Q2 Earnings Call Flags Stronger Second-Half SetupZacks2d ago
- Abbott Laboratories Seen on Track for H2 Growth Acceleration, RBC SaysMT Newswires2d ago
- BTIG Adjusts Price Target on Abbott Laboratories to $134 From $131, Maintains Buy RatingMT Newswires2d ago
- Piper Sandler Adjusts Price Target on Abbott Laboratories to $118 From $115, Maintains Overweight RatingMT Newswires2d ago
- JPMorgan Adjusts Price Target on Abbott Laboratories to $120 From $110, Maintains Overweight RatingMT Newswires2d ago
- Evercore ISI Adjusts Price Target on Abbott Laboratories to $120 From $112, Maintains Outperform RatingMT Newswires2d ago
Associés
Autres actifs de cette catégorie.
- 8306.TMitsubishi UFJ Financial Group, Inc.3,473 USD-4.30%
- 7203.TToyota Motor Corporation2,899.5 USD-0.33%
- 9984.TSoftBank Group Corp.5,424 USD-9.01%
- 6758.TSony Group Corporation3,470 USD+0.93%
- 6861.TKeyence Corporation70,880 USD-4.28%
- NVDANVIDIA Corporation202.81 USD-2.21%
- AAPLApple Inc.333.74 USD+0.14%
- 0700.HKTencent Holdings Limited477.8 USD+3.51%
Discussion en direct
Connexion to join the discussion.
- Aucun commentaire. Soyez le premier.